VivoSeq
Oncology

Metastatic Castration-Resistant Prostate Cancer, Mcrpc

9

Pipeline Programs↗

6

Active Trials↗

8

Companies Involved↗

Metastatic Castration-resistant Prostate Cancer, mCRPC is an early-stage landscape with 9 programs across 8 companies. The most active players are VitsGen Therapeutics Inc., Amgen, Pfizer.

Intelligence

Pipeline Metrics

Competitive Density

38/100

Pipeline Velocity

15/100

Mech. Concentration

33/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

V

VitsGen Therapeutics Inc.

1 program

Phase 1Amgen logo

Amgen

1 program

Phase 1Pfizer logo

Pfizer

1 program

Phase 1Astellas logo

Astellas

1 program

Phase 1S

Sebela Pharmaceuticals Development LLC

1 program

Phase 1Novartis logo

Novartis

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

71%

Small molecule

5 of 7 classified programs — the dominant modality here.

29%ALL OTHERSMonoclonal antibody114%Radiopharmaceutical114%

Small molecule leads; the ring shows all 7 classified programs, each share of the total. Modality classified for 89% of 9 pipeline programs.

Analysis

Trial Status

6

clinical trials

Recruiting4 · 67%
Active, not recruiting1 · 17%
Not yet recruiting1 · 17%

Clinical Trials

Trial Activity

6 trials

A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF 06821497 (MEVROMETOSTAT) IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC), CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)
Recruiting·Pfizer logoPfizer·Phase 1·NCT03460977·453 enrolled
A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression
Recruiting·Regeneron logoRegeneron·Preclinical·NCT03972657·345 enrolled
A Phase 1b, Open-label Study of Xaluritamig (AMG 509) in Adults With Metastatic Castration-resistant Prostate Cancer
Recruiting·Amgen logoAmgen·Phase 1·NCT07493512·40 enrolled
A Phase 1, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Biodistribution, Radiation Dosimetry and Preliminary Efficacy of 177Lu-PSMA-VG01 Injection in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Recruiting·VVitsGen Therapeutics Inc.·Phase 1·NCT07660211·10 enrolled
An Open-label Dosimetry, Biodistribution, Tolerability and Safety Study of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) With Moderately and Severely Impaired and With Normal Renal Function.
Active, not recruiting·Novartis logoNovartis·Phase 2·NCT06004661·23 enrolled
Non-Interventional, Observational, Retrospective and Prospective, Single- Arm Study to Assess the Effectiveness of Olaparib and Abiraterone Combination as First Line Therapy in NHA Pre-exposed mCRPC Patients in the GCC Region
Not yet recruiting·AstraZeneca logoAstraZeneca·N/A·NCT07674121·75 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)